Stomach Neoplasms: Clinical Trials

3,190 trials for Stomach Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1167 completed, 830 unknown, 534 recruiting, 209 terminated. 1088 Phase 2, 658 Phase 1, 577 Not applicable, 301 Phase 3, 66 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21088Completed 373, Unknown 285, Recruiting 161, Terminated 100, Not yet recruiting 70, Active not recruiting 66, Withdrawn 25, Suspended 7, Enrolling by invitation 1
Phase 1658Completed 247, Recruiting 125, Unknown 92, Terminated 88, Active not recruiting 60, Withdrawn 21, Not yet recruiting 17, Suspended 6, Enrolling by invitation 2
Not applicable577Completed 200, Unknown 166, Recruiting 113, Not yet recruiting 50, Active not recruiting 19, Terminated 15, Withdrawn 10, Enrolling by invitation 3, Suspended 1
Phase 3301Completed 120, Unknown 82, Recruiting 46, Terminated 21, Active not recruiting 14, Not yet recruiting 13, Withdrawn 5
Phase 466Completed 26, Unknown 21, Not yet recruiting 10, Recruiting 5, Terminated 2, Suspended 1, Withdrawn 1
Early Phase 136Unknown 13, Completed 6, Recruiting 6, Enrolling by invitation 3, Not yet recruiting 3, Terminated 3, Active not recruiting 1, Withdrawn 1

Follow Stomach Neoplasms: new trials by email Literature Review of Stomach Neoplasms trials Research Report on Stomach Neoplasms

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Pembrolizumab and either Capcecitabine + Oxaliplatin or Oxaliplatin+Leucovorin + 5-fluorouracil - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 3Not yet recruitingTranscenta Therapeutics (Hangzhou) Co., Ltd.8202027-06-302026-09-29
A Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal Adenocarcinoma
ONO-4578, Placebo, Nivolumab - Gastric Cancer, Esophagogastric Junction Cancer
Phase 3Not yet recruitingOno Pharmaceutical Co., Ltd.6002027-02-012026-09-14
Combination of CT and Ultrasound Radiomics Combined With Liquid Biopsy to Predict Neoadjuvant Chemotherapy Response in Patients With Locally Advanced Gastric Cancer
Gastric Cancer
Not yet recruitingLiu Yang3002027-02-012026-07-13
Zolbetuximab and Other Cancer Treatments in People With Advanced Gastric or GEJ Cancer in Clinical Practice (RADIANCE)
Zolbetuximab Exposure, Platinum-based Chemotherapy Exposure, 1L Treatment Not Containing Zolbetuximab Exposure - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Not yet recruitingAstellas Pharma Europe Ltd.10002027-01-312026-10-28
TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)
Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer
Not applicableNot yet recruitingCase Comprehensive Cancer Center202027-01-012026-08-05
Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC
Neoadjuvant SOX chemotherapy combined with PD-1 inhibitor - Stomach Neoplasms, Gastric Cancer (Diagnosis)
Not yet recruitingHainan General Hospital1032027-01-012026-10-28
Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
Apatinib Mesylate Tablets - Gastric Cancer, Surgery
Phase 3Not yet recruitingFujian Medical University1182026-12-252026-01-02
Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma
Serplulimab, Docetaxel, Oxaliplatin, S1, and Lenvatinib combined with PIPAC - Gastric/Gastroesophageal Junction Adenocarcinoma, Oligometastatic Peritoneal Metastasis
Phase 2Not yet recruitingFujian Cancer Hospital422026-12-152026-10-29
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
Radical Gastrectomy with D2 Lymphadenectomy, Standard Systemic Therapy for Advanced Gastric Cancer - Gastric Cancer, Peritoneal Metastasis
Phase 3RecruitingHua Huang, MD, PhD1702026-12-012026-10-16
A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Refractory to ≥ Second-Line Chemotherapy
TAS102+Nedaplatin - Gastric Cancer (GC)
Phase 2Not yet recruitingTao Zhang362026-12-012026-11-03
SND002 Cell Injection in Participants With Advanced Malignant Solid Tumors
SND002 Cell Injection - Colorectal Neoplasms, Stomach Neoplasms
Phase 1Not yet recruitingGuizhou Sinorda Pharmaceutical Co., Ltd.782026-12-012026-11-04
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
LY4336619, Sofetabart Mipitecan (Sofe-M) - Endometrial Neoplasms, Ovarian Neoplasms
Phase 1Not yet recruitingEli Lilly and Company3702026-12-012026-11-10
HLX22 Plus Serplulimab and Trastuzumab or Pertuzumab in HER2-Low Advanced Gastrointestinal Cancers
HLX22, Serplulimab, trastuzumab - Gastric Cancer (Diagnosis), Colorectal Cancer (Diagnosis)
Phase 2Not yet recruitingUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology1282026-12-012026-11-16
HLX22 Combination Therapy in HER2-Positive Limited Metastatic Gastric Cancer
HLX22, Trastuzumab, XELOX Chemotherapy - HER2-Positive, Limited Metastatic
Phase 2Not yet recruitingShanghai Zhongshan Hospital302026-12-012026-11-17
Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA
Zanidatamab - Esophageal Cancer, GastroEsophageal Cancer
Not yet recruitingJazz Pharmaceuticals3002026-11-302026-10-26
A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer
Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer
Phase 4Not yet recruitingAstellas Pharma Global Development, Inc.502026-11-302026-09-21
Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors
REGN13089-M404-M2980 - Advanced Solid Tumors
Phase 1 / Phase 2Not yet recruitingRegeneron Pharmaceuticals3202026-11-232026-10-07
Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis
Retlirafusp alfa + nab-paclitaxel + apatinib, HEPIC - Gastric Cancer (Diagnosis)
Phase 2Not yet recruitingAnhui Provincial Cancer Hospital322026-11-202026-10-29
Biomarker Investigation for Early Gastric Cancer Detection
Saliva sampling, Gastric juice sampling, Blood sampling - Gastro Oesophageal Cancer
Not applicableRecruitingCentre Leon Berard1002026-11-122026-11-17
A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)
Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms
Phase 4Not yet recruitingMerck Sharp & Dohme LLC1502026-11-062026-09-03

Showing 20 of 3190. Sign in to see all of them.

Narrower conditions

Esophageal Neoplasms (557)  ·  Pancreatic Neoplasms (395)  ·  Colorectal Neoplasms (371)  ·  Breast Neoplasms (301)  ·  Carcinoma, Non-Small-Cell Lung (234)  ·  Ovarian Neoplasms (233)  ·  Neoplasms (214)  ·  Lung Neoplasms (204)  ·  Colonic Neoplasms (199)  ·  Carcinoma, Hepatocellular (153)  ·  Neoplasm Metastasis (150)  ·  Liver Neoplasms (145)  ·  Urinary Bladder Neoplasms (144)  ·  Uterine Cervical Neoplasms (135)

Broader conditions

Digestive System Diseases (3184)  ·  Neoplasms by Site (3180)  ·  Stomach Diseases (3180)  ·  Gastrointestinal Diseases (3175)  ·  Digestive System Neoplasms (3171)  ·  Gastrointestinal Neoplasms (3098)  ·  Neoplasms (2976)  ·  Intestinal Diseases (597)  ·  Esophageal Diseases (587)  ·  Neoplasms by Histologic Type (570)  ·  Head and Neck Neoplasms (562)  ·  Intestinal Neoplasms (555)  ·  Endocrine System Diseases (548)  ·  Endocrine Gland Neoplasms (539)  ·  Colonic Diseases (534)

Interventions

Oxaliplatin (307)  ·  Capecitabine (218)  ·  Fluorouracil (190)  ·  Cisplatin (173)  ·  Docetaxel (144)  ·  S 1 (combination) (140)  ·  Paclitaxel (130)  ·  Leucovorin (122)  ·  pembrolizumab (113)  ·  Irinotecan (111)  ·  Trastuzumab (81)  ·  Nivolumab (64)  ·  apatinib (59)  ·  Drug Therapy (52)  ·  sintilimab (48)

Sponsors

Yonsei University (64)  ·  National Cancer Institute (NCI) (62)  ·  Fudan University (53)  ·  Fujian Medical University (47)  ·  Memorial Sloan Kettering Cancer Center (37)  ·  National Cancer Center, Korea (37)  ·  Samsung Medical Center (36)  ·  Peking University (33)  ·  Tianjin Medical University Cancer Institute and Hospital (33)  ·  Shanghai Zhongshan Hospital (28)  ·  Asan Medical Center (27)  ·  AstraZeneca (27)  ·  Sun Yat-sen University (27)  ·  The First Affiliated Hospital with Nanjing Medical University (27)  ·  Hoffmann-La Roche (25)

Countries

China (1073)  ·  United States (778)  ·  South Korea (480)  ·  Japan (179)  ·  Spain (169)  ·  France (156)  ·  Italy (156)  ·  Germany (155)  ·  United Kingdom (154)  ·  Taiwan (139)  ·  Canada (107)  ·  Australia (106)  ·  Belgium (78)  ·  Netherlands (77)  ·  Poland (66)

Top investigators

Changming Huang, Professor (8)  ·  Yelena Janjigian, MD (8)  ·  Jiafu Ji, MD (6)  ·  Lin Shen, MD (6)  ·  Chen Li, PH D (5)  ·  Han Liang, Master (5)

Results publications

PMID 35623069, PMID 40341124, PMID 20728210, PMID 40340830, PMID 33538338, PMID 33792646, PMID 38421211, PMID 15273542, PMID 22226517, PMID 24714327, PMID 30982686, PMID 35219300, PMID 35692051, PMID 37037952, PMID 38308771, PMID 38980664, PMID 39089261, PMID 40117530, PMID 11813623, PMID 16822992, PMID 17978289, PMID 18669424, PMID 18948798, PMID 21104822, PMID 21444866, PMID 22189752, PMID 23207683, PMID 23403142, PMID 24094768, PMID 24399492, PMID 24618998, PMID 25240821, PMID 25939684, PMID 26352529, PMID 26542081, PMID 26566136, PMID 26808342, PMID 26857702, PMID 27156933, PMID 27641243, PMID 27776843, PMID 28716815, PMID 29543932, PMID 30557792, PMID 30566590, PMID 30911859, PMID 31513484, PMID 32101269, PMID 33763656, PMID 34197702

NIH funding

2023 (28), 2017 (12), 2019 (12), 2018 (11), 2014 (10), 2015 (9), 2025 (9), 2016 (7), P30CA033572 (6), P30CA016087 (5), P30CA068485 (5), U10CA032102 (5), 2009 (4), 2008 (3), P30CA008748 (3)